Jefferies Financial Group Inc. acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 40,000 shares of the company's stock, valued at approximately $473,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its stake in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after buying an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Roivant Sciences in the 4th quarter valued at about $39,000. PNC Financial Services Group Inc. lifted its stake in Roivant Sciences by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after purchasing an additional 1,507 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Roivant Sciences by 84.1% during the 4th quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock worth $89,000 after purchasing an additional 3,426 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Roivant Sciences by 550.1% during the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock worth $91,000 after purchasing an additional 6,667 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.
Roivant Sciences Stock Up 0.0%
Shares of Roivant Sciences stock traded up $0.01 during mid-day trading on Thursday, hitting $10.92. The stock had a trading volume of 614,317 shares, compared to its average volume of 5,572,736. The firm has a 50-day moving average of $10.53 and a two-hundred day moving average of $11.07. The firm has a market cap of $7.79 billion, a P/E ratio of -72.76 and a beta of 1.23. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $13.06.
Analyst Ratings Changes
Several equities research analysts recently commented on ROIV shares. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Monday, April 21st. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.
Read Our Latest Stock Analysis on ROIV
Insider Activity
In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 273,959 shares of the firm's stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the completion of the sale, the insider now owns 39,799,611 shares of the company's stock, valued at $456,501,538.17. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eric Venker sold 315,522 shares of the company's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $11.06, for a total value of $3,489,673.32. Following the completion of the transaction, the chief operating officer now directly owns 959,457 shares in the company, valued at approximately $10,611,594.42. This trade represents a 24.75% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,123,959 shares of company stock valued at $12,355,035. 7.90% of the stock is currently owned by company insiders.
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
